Clinical Trials
15 trialsNCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003614 2023-06-15
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04221828 2022-03-29
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Phase 2 Terminated
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00005028 2019-11-04
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT03077659 2019-08-20
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
NanOlogy, LLC
Phase 2 Completed
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT01558492 2017-06-09
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00151060 2015-01-21
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00003717 2013-12-19
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00028769 2013-07-16
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00084565 2013-07-10
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00193193 2010-08-04
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed